Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo
These results support the investigation of ALXN2420 as a combination therapy for the treatment of patients with acromegaly inadequately controlled by SSAs.
Authors
- Patrick Reid
- Haruaki Kurasaki (ORCID: https://orcid.org/0000-0003-4276-0545)
- Michael D. Culler (ORCID: https://orcid.org/0000-0001-5168-8739)
- Corentin Berardet
- Clémentine Chalmey (ORCID: https://orcid.org/0000-0002-1874-2876)
- Rakesh Datta (ORCID: https://orcid.org/0000-0002-5695-3017)
- Tatsuya Tomiyama
- David Duracher
- Myriam Aouadi (ORCID: https://orcid.org/0000-0001-6256-7107)
- Xavier Gaume (ORCID: https://orcid.org/0000-0003-0097-4609)
- Guillaume Ravel
Institutions
- AstraZeneca (France) (FR)
- Alexion Pharmaceuticals (United States) (US)
- AstraZeneca (United States) (US)
- Peptidream (Japan) (JP)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1093/ejendo/lvaf043
- Citations
- 3
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.88